# Therapy Toxicities

Rahul Shah

---

## Immune Checkpoint Inhibitor Toxicities

- Immune checkpoint inhibitors augment the endogenous immune response
    against tumors, which may lead to autoimmune-like toxicities, known
    as immune-related adverse events (irAEs)
- Treatment: low-dose glucocorticoids (prednisone, 0.5 mg/kg) for mild
    adverse events, high dose glucocorticoids (prednisone, 1-2 mg/kg)
    for severe adverse events

<table>
<colgroup>
<col style="width: 31%" />
<col style="width: 32%" />
<col style="width: 36%" />
</colgroup>
<thead>
<tr class="header">
<th>Adverse Event Type</th>
<th><p>Incidence with anti-CTLA-4</p>
<p>(e.g. ipilimumab)</p></th>
<th><p>Incidence with anti‐PD1/PD‐L1</p>
<p>(e.g. nivolumab, pembrolizumab)</p></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Skin (rash, pruritus, TEN)</td>
<td>30%</td>
<td>30%</td>
</tr>
<tr class="even">
<td>Colitis</td>
<td>25%</td>
<td>5%</td>
</tr>
<tr class="odd">
<td>Hypothyroidism</td>
<td>20%</td>
<td>20%</td>
</tr>
<tr class="even">
<td>Hepatitis</td>
<td>10%</td>
<td>1%</td>
</tr>
<tr class="odd">
<td>Hypophysitis</td>
<td>10%</td>
<td>rare</td>
</tr>
<tr class="even">
<td>Pneumonitis</td>
<td>2-5%</td>
<td>2-5%</td>
</tr>
<tr class="odd">
<td>Myocarditis</td>
<td>&lt;1%</td>
<td>&lt;1%</td>
</tr>
<tr class="even">
<td>Neurotoxicity (GBS, myasthenia gravis, encephalitis)</td>
<td>&lt;1%</td>
<td>&lt;1%</td>
</tr>
</tbody>
</table>

## Cytotoxic Agent Toxicities

| Class                      | Agent                                                    |  Side Effect                                                                                                                                                                                                   |
|----------------------------|----------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Alkylating Agents          | Busulfan                                                 | Pulmonary fibrosis or diffuse alveolar hemorrhage                                                                                                                                                              |
|                            | Cyclophosphamide                                         | Myopericarditis, hemorrhagic cystitis (prevention: hydration; monitoring: daily UA, tx: mesna)                                                                                                                 |
|                            | Ifosfamide                                               | Encephalopathy (tx: methylene blue), nephrotoxicity, hemorrhagic cystitis                                                                                                                                      |
| Antimetabolites            | 5- Fluorouracil (5-FU)/ Capecitabine (metabolized to FU) | Myelosuppression, coronary vasospasm, palmar-plantar erythrodysesthesia, mucositis                                                                                                                             |
|                            | Cladribine, pentostatin                                  | Dose reduced for CrCl                                                                                                                                                                                          |
|                            | Cytarabine (Ara-C)                                       | Irreversible cerebellar ataxia (if high dose, neuro checks required), conjunctivitis (prevent with prophylactic steroid eye drops)                                                                             |
|                            | Gemcitabine                                              | Transient transaminitis, peripheral edema, rash, rarely: pulmonary toxicity, hemolytic uremic syndrome, capillary leak syndrome                                                                                |
|                            | Methotrexate                                             | Stomatitis, hepatotoxicity, renal failure, high dose requires leucovorin                                                                                                                                       |
| Antitumor antibiotics      | Anthracyclines (doxorubicin, daunorubicin, idarubicin)   | HFrEF (need TTE prior). Most notable with doxorubicin.                                                                                                                                                         |
|                            | Bleomycin                                                | Pulmonary fibrosis. Potentiated with G-CSF                                                                                                                                                                     |
| Monoclonal Antibodies      | Alemtuzumab                                              | Severe and prolonged cytopenias                                                                                                                                                                                |
|                            | Bevacizumab                                              | HFrEF, HTN, hyperglycemia, hypomag, DVT, pulm hemorrhage, GI bleeding/fistulas/perforation, wound healing complications                                                                                        |
|                            | Rituximab                                                | Hypophos, hepatotoxicity, HBV reactivation (screen all patients), peripheral neuropathy; transfusion reaction during 1<sup>st</sup> time infusion                                                              |
| Platinum Agents            | Cisplatin, oxaliplatin, carboplatin                      | Nephrotoxicity, worst with cisplatin. Rental tubular acidosis. Neurotoxicity (parasthesias, cold sensitivity, cramps, peripheral neuropathy), ototoxicity (high frequency hearing loss), constipation, hypomag |
| Taxanes                    | Docetaxel, paclitaxel                                    | Hypersensitivity reaction (often require premedication with steroids and H1/H2 blockers); peripheral neuropathy                                                                                                |
| Topoisomerase Inhibitors   | Irinotecan, topotecan, etoposide                         | Irinotecan- acute diarrhea can be treated with atropine; delayed with atropine                                                                                                                                 |
| Tyrosine Kinase Inhibitors | Imatinib, Dasatinib, Nilotinib, Bosutinib                | QTc prolongation, pulmonary effusion, hepatotoxicity                                                                                                                                                           |
| Vinca alkaloid             | Vincristine                                              | Peripheral neuropathy and ototoxicity (vestibular system lost first)                                                                                                                                           |
